FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317778970> ?p ?o ?g. }

• W4317778970 endingPage "369" @default.
• W4317778970 startingPage "363" @default.
• W4317778970 abstract "Cancer patients are more vulnerable to COVID-19 and are thus given high priority in vaccination campaigns. In solid cancer patients treated with checkpoint inhibitors, we evaluated the amount of anti-RBD and neutralizing antibodies and antibody avidity after two or three doses of the vaccine.Thirty-eight solid cancer patients, 15 untreated hematological patients and 21 healthy subjects were enrolled in the study. Blood was collected before the first dose (T0), 21 days after the second (T2) and in 18 solid cancer patients also 15 days after the third dose of vaccine (T3). IgG, IgM and IgA anti-RBD antibodies were detected by ELISA. Neutralizing antibodies were measured testing the inhibition of RBD binding to ACE2. Antibody avidity was evaluated in 18 patients by a urea avidity ELISA.IgG anti-RBD antibodies were produced in 65.8% of the cancer patients at T2, and in 60% of hematological patients at levels lower than healthy controls. IgM and IgA anti-RBD antibodies were also produced in 5.3% and 21% cancer patients, respectively. At T3, a significant increase in anti-RBD IgG levels was observed. Neutralizing antibodies were produced in 68.4% of cancer patients as compared with 93% of untreated hematological patients and 100% of controls, at titers lower than in healthy subjects. At T3, neutralizing antibodies and avidity of IgG anti-RBD increased; 6/18 patients negative at T2 developed neutralizing antibodies at T3.The data indicate that in cancer patients mRNA vaccine induces high avidity anti-RBD antibodies and neutralizing antibodies that increase after the third dose. The process of induction and selection of high-affinity antibodies is apparently unaffected by the treatment with anti-PD-1 or anti-PD-L1 antibodies." @default.
• W4317778970 created "2023-01-24" @default.
• W4317778970 creator A5010296562 @default.
• W4317778970 creator A5014405033 @default.
• W4317778970 creator A5016842063 @default.
• W4317778970 creator A5019141029 @default.
• W4317778970 creator A5024513740 @default.
• W4317778970 creator A5026345672 @default.
• W4317778970 creator A5038300856 @default.
• W4317778970 creator A5050399237 @default.
• W4317778970 creator A5068166657 @default.
• W4317778970 creator A5077474262 @default.
• W4317778970 creator A5085186522 @default.
• W4317778970 date "2023-01-23" @default.
• W4317778970 modified "2023-09-25" @default.
• W4317778970 title "Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies" @default.
• W4317778970 cites W2995903145 @default.
• W4317778970 cites W3028965239 @default.
• W4317778970 cites W3044482768 @default.
• W4317778970 cites W3117702394 @default.
• W4317778970 cites W3165390631 @default.
• W4317778970 cites W3174932895 @default.
• W4317778970 cites W3182782630 @default.
• W4317778970 cites W3183526712 @default.
• W4317778970 cites W3193789398 @default.
• W4317778970 cites W3197493891 @default.
• W4317778970 cites W3197610109 @default.
• W4317778970 cites W3198365285 @default.
• W4317778970 cites W3199253355 @default.
• W4317778970 cites W3200303519 @default.
• W4317778970 cites W3203139340 @default.
• W4317778970 cites W3204258336 @default.
• W4317778970 cites W3209203499 @default.
• W4317778970 cites W3215637620 @default.
• W4317778970 cites W3216196257 @default.
• W4317778970 cites W3216485885 @default.
• W4317778970 cites W4225569559 @default.
• W4317778970 cites W4225725936 @default.
• W4317778970 cites W4284705771 @default.
• W4317778970 doi "https://doi.org/10.1007/s10147-023-02295-0" @default.
• W4317778970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36689013" @default.
• W4317778970 hasPublicationYear "2023" @default.
• W4317778970 type Work @default.
• W4317778970 citedByCount "0" @default.
• W4317778970 crossrefType "journal-article" @default.
• W4317778970 hasAuthorship W4317778970A5010296562 @default.
• W4317778970 hasAuthorship W4317778970A5014405033 @default.
• W4317778970 hasAuthorship W4317778970A5016842063 @default.
• W4317778970 hasAuthorship W4317778970A5019141029 @default.
• W4317778970 hasAuthorship W4317778970A5024513740 @default.
• W4317778970 hasAuthorship W4317778970A5026345672 @default.
• W4317778970 hasAuthorship W4317778970A5038300856 @default.
• W4317778970 hasAuthorship W4317778970A5050399237 @default.
• W4317778970 hasAuthorship W4317778970A5068166657 @default.
• W4317778970 hasAuthorship W4317778970A5077474262 @default.
• W4317778970 hasAuthorship W4317778970A5085186522 @default.
• W4317778970 hasBestOaLocation W43177789701 @default.
• W4317778970 hasConcept C121608353 @default.
• W4317778970 hasConcept C126322002 @default.
• W4317778970 hasConcept C159047783 @default.
• W4317778970 hasConcept C159654299 @default.
• W4317778970 hasConcept C179223381 @default.
• W4317778970 hasConcept C203014093 @default.
• W4317778970 hasConcept C22070199 @default.
• W4317778970 hasConcept C2779261636 @default.
• W4317778970 hasConcept C32611913 @default.
• W4317778970 hasConcept C71924100 @default.
• W4317778970 hasConceptScore W4317778970C121608353 @default.
• W4317778970 hasConceptScore W4317778970C126322002 @default.
• W4317778970 hasConceptScore W4317778970C159047783 @default.
• W4317778970 hasConceptScore W4317778970C159654299 @default.
• W4317778970 hasConceptScore W4317778970C179223381 @default.
• W4317778970 hasConceptScore W4317778970C203014093 @default.
• W4317778970 hasConceptScore W4317778970C22070199 @default.
• W4317778970 hasConceptScore W4317778970C2779261636 @default.
• W4317778970 hasConceptScore W4317778970C32611913 @default.
• W4317778970 hasConceptScore W4317778970C71924100 @default.
• W4317778970 hasFunder F4320321781 @default.
• W4317778970 hasFunder F4320324499 @default.
• W4317778970 hasIssue "3" @default.
• W4317778970 hasLocation W43177789701 @default.
• W4317778970 hasLocation W43177789702 @default.
• W4317778970 hasLocation W43177789703 @default.
• W4317778970 hasOpenAccess W4317778970 @default.
• W4317778970 hasPrimaryLocation W43177789701 @default.
• W4317778970 hasRelatedWork W1693544388 @default.
• W4317778970 hasRelatedWork W1972745941 @default.
• W4317778970 hasRelatedWork W1984647379 @default.
• W4317778970 hasRelatedWork W2029718265 @default.
• W4317778970 hasRelatedWork W2364746690 @default.
• W4317778970 hasRelatedWork W3092495366 @default.
• W4317778970 hasRelatedWork W3125277340 @default.
• W4317778970 hasRelatedWork W4205873719 @default.
• W4317778970 hasRelatedWork W4225282409 @default.
• W4317778970 hasRelatedWork W4289529812 @default.
• W4317778970 hasVolume "28" @default.
• W4317778970 isParatext "false" @default.
• W4317778970 isRetracted "false" @default.

• next